Combination of Ranibizumab and Verteporfin Therapy in Neovascular Age-related Macular Degeneration

Changes in Preferential Hyperacuity Perimeter (PHP) and Fundus Autofluorescence (FAF) in Patients With Neovascular Age-related Macular Degeneration Receiving Combination of Ranibizumab and Verteporfin Therapy

The purpose of this study is to evaluate changes in preferential hyperacuity perimeter (PHP) and fundus autofluorescence (FAF) in patients with neovascular age-related macular degeneration receiving combination of ranibizumab (LucentisTM) and verteporfin (Visudyne®) therapy

Inclusion Criteria:

• Signed written informed consent

• Age ≥ 50 years old

• Patients with primary active subfoveal CNV secondary to AMD

• Baseline best-corrected visual acuity (BCVA) in the study eye was from 20/40 to 20/400 using ETDRS chart

• Characteristics of AMD lesion

  • predominantly or minimally classic, or occult
  • absence of prior subfoveal treatment for macular disease
  • total lesion size ≤ 9 optic disc areas, with CNV component ≥ 50% of the lesion (unless a serous pigment epithelial detachment was present, in which case < 50% CNV was acceptable)
  • active choroidal neovascularization leakage
  • submacular blood < 50% and subretinal fibrosis < 25% of the total lesion

Exclusion Criteria:

• additional eye disease that could compromise VA
• CNV unrelated to AMD
• ocular inflammation
• vitreous hemorrhage
• retinal hemorrhage (other than AMD related submacular blood) > 1 disc areas
• intraocular surgery ≤ 1 month before day 0
• uncontrolled glaucoma
• prior treatments with verteporfin PDT
• laser photocoagulation or other intervention for AMD
• previous treatment with external-beam radiation therapy or transpupillary thermotherapy
• history of vitrectomy